AbbVie Says All Three Zumilokibart Dose Regimens Met Primary Endpoint With Significantly Greater EASI-75 Response Vs Placebo At Week 16 In Phase 2 APEX Part B Atopic Dermatitis Study
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response
Share
Why It Matters
AbbVie tested a new skin medicine called zumilokibart on people with severe eczema. All three dose amounts worked better than fake medicine, which is a good sign for the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.